Board of Directors
Gregory J. Galvin, Ph.D.
President, Chief Executive Officer and Chairman of the Board of DirectorsView Bio
Dr. Galvin has been at the forefront of multidisciplinary technology commercialization since 1993, when he launched Kionix Inc. to commercialize a novel micro-electro-mechanical system (MEMS) technology platform. Dr. Galvin sold the Kionix telecommunications platform to Calient Networks Inc. in 2000 and purchased the rights to the name and access to certain markets in 2001. Dr. Galvin continued his successful commercialization of Kionix with applications in MEMS technology for semiconductor applications including a highly successful accelerometer product for smartphones. Dr. Galvin spun out Rheonix Inc. from Kionix in 2008 to capitalize on non-MEMS-based microfluidic opportunities in the molecular diagnostics industry and sold the second incarnation of Kionix Inc. to Rohm Co. Ltd.
Dr. Galvin is a member of several scientific societies, has published more than 20 technical papers and holds 58 patents. He is a member of the Advisory Councils of the Cornell Engineering College, Entrepreneurship at Cornell and the Cornell Materials Science Department and has served as a member of the Cornell Board of Trustees. He also serves as a director of the Boyce Thompson Institute for Plant Research, the El Portal de Belén Foundation and Ithaca's Sciencenter. He was named Cornell Entrepreneur of the Year 2014.
He holds a B.S. from the California Institute of Technology in electrical engineering and a Ph.D. in materials science and MBA from Cornell University.
Mr. Proujansky is managing partner of Cayuga Venture Fund IV and a founding member of CVF since 1996. He is also a founding Managing Partner of Integrated Acquisition & Development (IAD), a diversified commercial real estate organization and a private equity investor. Mr. Proujansky serves on the boards of Rheonix and Mezmeriz and is a board observer at Calient Technologies, Inc. Mr. Proujansky was also on the boards of Kionix prior to its sale in November 2009, Instinctiv before it was acquired by SoundCloud in May 2012, and BinOptics prior to its sale in December 2014. He has previously been a founding and principal investor in a number of startup technology-based businesses. Mr. Proujansky serves on the Cornell Tech Transfer Advisory Committee, Cornell Real Estate Advisory Board, the Paleontological Research Institution, and several other not-for-profit organizations and institutions.
He earned his B.S. in engineering physics at Cornell University. Mr. Proujansky has previously been a principal investor in a number of startup technology-based businesses, including companies in the development of "non-wireline" cellular telephone MSA and RSA markets, as well as in companies with expertise in artificial intelligence for industrial applications. Mr. Proujansky began his career as a financial analyst and consultant after studying engineering physics at Cornell University. In 1975 he began working in Ithaca, NY, with his two IAD co-managing partners in acquisition, development, finance, leasing and management of commercial and multi-residential real estate.
Allen “Pete” Grum
Since 1995, Pete Grum has been the president, chief executive officer and director of Rand Capital Corporation (NASDAQ:RAND). Rand Capital has $35 million in investments in 30+ companies. These companies have increased employment by over 500 jobs and increased their revenues by $170 million in the past five years. He is on the board of many companies including Carolina Skiff LLC, Gemcor II LLC, Mezmeriz Inc., Microcision LLC, New Monarch Machine Tool Inc., OnCore Golf Technology Inc., SocialFlow Inc., Reeds Jewelers, and Invision Health. For the past 15 years he has been active with Buffalo State College and is currently a member of the College Council. Previously he was active in many roles with the Buffalo State College Foundation, including chairman of the Investment Committee. He is on the Investment Committee of the Kaleida Health Systems, University of Buffalo Foundation and The Community Foundation. He is the previous chairman and current board member of Horizon Health Services. Pete has an MBA from Rochester Institute of Technology and a B.A. in economics from Eisenhower College. He lives in the City of Buffalo.
Xinqun Lu joined Beijing Bohui Innovation Optoelectronic Technology Co., Ltd., a publicly traded in vitro diagnostics company located in Beijing, China, as the president and CEO in January 2014. Under his leadership, Bohui completed two major acquisitions in 2014, the U.S. mass spectrometry company Advion and a Chinese blood product company. He served as director, CFO, vice president and HR director of Jungzheng Energy & Chemical Company (listed in Shanghai Stock Exchange) for eight years. In this capacity, he helped the CEO to build Jungzheng from the ground up until its initial public offering. Xinqun also serves as a director of the Tianhong fund, one of the largest asset management companies in China.
Bill Colston, Ph.D.
Dr. Colston is currently the CEO of HealthTell, an early stage life sciences company that utilizes an Immunosignature™ Technology for accurate and timely detection and monitoring of more than 30 progressive diseases. He was previously the CEO and scientific founder of QuantaLife Inc., a successful biotechnology startup company that developed the most accurate genetic analysis system in the world (droplet digital PCR™). Dr. Colston raised multiple rounds of private funding, moving from concept to manufactured product in a fraction of the time of comparable companies in this space. QuantaLife grew exponentially during his tenure, from the four scientific founders during the inception of the company in 2008 to over 60 employees by the time it was sold to Bio-Rad Inc. in 2011. Prior to QuantaLife, Dr. Colston worked within the University of California (UC) National Labs for almost 20 years, ultimately serving in multiple different senior leadership roles. A prolific scientific writer and inventor, he has authored numerous publications and patents. Dr. Colston received his B.S. in biology from the University of Texas, Austin and his Ph.D. in biomedical engineering from the University of California, Davis.
David B. Patteson
David B. Patteson serves as CEO of Advion Inc., a life science instrument business acquired by Bohui Innovation Technology in 2015. David also served as CEO of Advion BioSciences, a bioanalytical CRO acquired by Quintiles Transnational in 2011, and CEO of Biotage Inc., acquired by Pyrosequencing AB in 2003. Prior to Biotage, Mr. Patteson led a multi-hundred million dollar business group for the UK-based global engineering and instrumentation company Invensys, and prior to Invensys was president of Perstorp Analytical, Inc. Mr. Patteson’s career spans over 35 years of analytical, process, synthetic organic chemistry instrumentation and CRO business experience. His passions involve strategic planning, acquisitions/integration, global expansion, and profit enhancement. Dave also serves as chairman of Gyros Protein Technologies Inc. (GPT), a world leader in immunoassay and peptide synthesis systems and consumables, and chairman of Gene Solutions LLC, a CNS therapeutic and molecular diagnostic company he co-founded in 2006. He also serves as an operating partner for Ampersand Capital Partners, a major shareholder of GPT.